James Rozsa

+61 2 8274 9541
+61 419 012 294


James is a corporate lawyer specialising in mergers and acquisitions, private equity transactions and equity capital markets.

He advises clients from a variety of industries including private equity sponsors. He is an expert in all aspects of domestic and cross-border M&A deals including public (takeovers and schemes of arrangements) and privately negotiated transactions and ECM deals including cross-border listings on the ASX.

James is qualified in both Australia and the US, and has for many years advised US clients doing business in Australia and Australian clients doing business in the US.

James has been consistently recognised by his peers (Best Lawyers) for each of M&A, Private Equity (2010-2018) and by his clients (Chambers) as a leading individual, again for each of Corporate/M&A, Private Equity (2011-2016) and Capital Markets (2016). In Chambers he is described as “easily the best private equity lawyer we have dealt with, especially on cross-border deals” and is regarded as a "solutions-based lawyer who is very hands-on during a deal" and is lauded for producing "high-quality work quickly and with strong client interaction.”


Private Equity M&A

  • AIM: acting for the Australian Institute of Management in relation to CHAMP Venture’s investment into AIM’s training business.
  • Arboretum Ventures: acting as Australian counsel for Arboretum Ventures, a Michigan-based venture capital firm specialising in the healthcare sector, in its participation in Cardiac Dimensions equity financing.
  • Archer Capital: acting in relation to Archer’s acquisition of Dun & Bradstreet’s Australian and New Zealand businesses; secondary buy-out of mining services business LCR Group; acquisition of Lend Lease’s Primelife Aged Care business; acquisition of the V8 Supercars business; and secondary buy-out of flight services business Aero-Care.
  • Calera Capital: acting in relation to its acquisition of Transaction Services Group.
  • Canberra Data Centres: acting for CDC and its shareholders in their partial divestment to Quadrant Private Equity.
  • Insight Venture Partners: acting for Gettheworldmoving in its sale to Virgin Pulse, a portfolio company of Insight.
  • Insight Venture Partnersacting in relation to Insight’s acquisition of Yuruware from NICTA; and in relation to Insight’s investment in email marketing business Campaign Monitor.
  • L Capital Asia: acting in relation to its investment in swimwear company Seafolly; its investment in sports apparel company 2XU; and its acquisition of iconic Australian boot maker RM Williams.
  • Virgin Active Australiaacting for Virgin Active Australia and Virgin Group in the $1 billion divestment of 51% of the Virgin Active business to CVC.

Mergers & Acquisitions

  • Andean Resources (ASX: AND)acting in its $3.6 billion acquisition of GoldCorp Inc.
  • EnGeneIC Ltd: acting for EnGeneIC in its redomicile by schemes of arrangement to Bermuda.
  • LiveOps Incacting in its acquisition of all of the assets of Datasquirt Ltd (ASX:DSQ).
  • Peplin Inc (ASX:PLI)acting on its $300 million merger with LEO Pharma.
  • Presidian: acting for Presidian (a specialist finance, warranty and motor insurance provider) and its shareholders in the sale of Presidian to McMillan Shakespeare Ltd (ASX:MMS).
  • Seven: acting for Seven Group Holdings in its investment in iSeekplant.
  • SingTel’s Amobeeacting as Australian counsel in relation to Amobee’s acquisition of Adconion.
  • Virgin Groupacting in relation to Virgin’s sale of Virgin Money Australia to Bank of Queensland (ASX:BOQ).
  • Vocation Ltd (ASX:VET)acting in relation to VET’s acquisition of Endeavour Learning and Real Institute.
  • Vodafone Groupacting on the A$8 billion merger with Hutchison, and advised in relation to the acquisition of Crazy John’s.

Equity Capital Markets

  • AirXpanders Inc (ASX:AXP): acting for AXP on its Australian IPO and ASX-listing.
  • BSA Ltd (ASX:BSA): acting for BSA in its placement and underwritten pro-rata entitlement offer.
  • Energy World Corporation(ASX:EWC)acting in relation to its PIPE by Standard Chartered Private Equity.
  • ImpediMed Ltd (ASX:IPD): acting for IPD in various fundraisings, including its underwritten pro-rata entitlement offer and placement
  • Kai Medical Incacting on its proposed IPO and ASX-listing.
  • Novo A/S: acting as Australian counsel in its financing of Spinifex.
  • Osprey Medical Inc (ASX:OSP): acting in relation to OSP’s private placement of CDIs.
  • Sunshine Heart (ASX:SHC): acting in relation to SHC’s concurrent private placement of CDIs and (as Australian counsel) its IPO and Nasdaq-listing.
  • Uptake Medical Incacting on its proposed IPO and ASX-listing.
  • Vocation Ltd (ASX:VET): acting in relation to VET’s IPO and ASX-listing.


  • Ranked as a leading lawyer in Corporate/M&A and Private Equity – Chambers Asia-Pacific, 2014
  • Recognised as a leading lawyer in Private Equity, Mergers and Acquisitions and Equity Capital Markets Law – Best Lawyers Australia, 2018
  • James Rozsa is described as a "solutions-based lawyer who is very hands-on during a deal," and is also lauded for producing "high-quality work quickly and with strong client interaction." Chambers Asia-Pacific, 2014
  • James Rozsa is praised by clients for his "tireless work on documentation" and for proving "good in both service and content." - Chambers Asia-Pacific, 2014


  • Bachelor of Laws, Sydney University
  • Bachelor of Arts, Sydney University
  • New York State Bar

International experience

  • Qualified in both Australia and the US, James has closed many deals around the world, including in Sydney, New York, London, Milan, Stockholm and Beijing.
  • James also has experience in North America and Europe as an investment banker.
  • James has for many years advised US clients doing business in Australia and Australian clients doing business in the US, including a number of US med-tech companies on their proposed Australian IPOs and ASX-listings.